Kathleen P. Bloch - Nov 23, 2021 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role
Chief Financial Officer
Signature
/s/ Kathleen P. Bloch
Stock symbol
CTSO
Transactions as of
Nov 23, 2021
Transactions value $
$19,920
Form type
4
Date filed
11/26/2021, 05:11 PM
Next filing
Jun 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTSO Common Stock Purchase $19.9K +4K +19.05% $4.98 25K Nov 23, 2021 See Footnote F1
holding CTSO Common Stock 361K Nov 23, 2021 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account and (ii) 15,000 shares held by the Reporting Person's husband in an IRA account (including the 4,000 shares reported on this Form 4). The Reporting Person may be deemed the beneficial owner of such shares.
F2 Includes the following RSUs that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015.
F3 Includes the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: (a) 32,967 RSUs granted on April 12, 2021 and unvested as of the date hereof, and (b) 14,334 RSUs granted on February 28, 2020 and unvested as of the date hereof.
F4 Includes 132,632 shares of Common Stock owned by the Reporting Person.